A 58-year-old woman with a 10-year history of vitiligo presents with a solitary, rapidly enlarging, darkly pigmented nodule on the dorsal surface of her right foot. Dermoscopy reveals a polymorphous vascular pattern with irregular dots and globules. Histopathology shows nests of epithelioid melanocytes with moderate nuclear pleomorphism, scattered mitotic figures (8 per 10 high-power fields), and a brisk lymphocytic infiltrate at the base. The lesion measures 1.2 cm in maximum dimension. Which of the following is the single most important adverse prognostic factor in this case?

Explanation

## Prognostic Factors in Cutaneous Melanoma ### Clark Level vs Breslow Thickness While both Clark level and Breslow thickness are important prognostic parameters, **Breslow thickness** (measured in millimeters from the granular layer to the deepest tumor cell) is the **single most reproducible and powerful independent prognostic indicator** in melanoma. However, this question specifically addresses **location** as a prognostic factor. ### Acral Lentiginous Melanoma (ALM) — The Key Concept **High-Yield:** Acral lentiginous melanoma (ALM) is a distinct subtype that arises on non-hair-bearing, pressure-bearing surfaces (palms, soles, nail beds, and mucosal surfaces). Despite comprising only 5–10% of melanomas in Caucasians, ALM has a **significantly worse prognosis** than other subtypes, even when controlling for Breslow thickness and Clark level. ### Why Acral Location Is the Answer | Feature | Acral Lentiginous Melanoma | Cutaneous Melanoma (Other Sites) | |---------|---------------------------|----------------------------------| | Incidence | 5–10% of melanomas in Caucasians; up to 50% in darker-skinned populations | 90% of melanomas | | Breslow thickness at diagnosis | Often >4 mm (thick) | Variable | | 5-year survival (matched thickness) | 50–60% | 75–85% | | Median survival | Significantly worse | Better | | Reason for poor prognosis | Delayed diagnosis (thick at presentation), high propensity for early lymph node involvement, aggressive biology | Earlier detection, better prognosis | **Clinical Pearl:** The foot (especially the sole) is a classic location for ALM. The combination of acral location + rapid growth + epithelioid morphology + moderate mitotic rate in this 58-year-old woman is highly suggestive of ALM with unfavorable prognosis. ### Why Other Options Are NOT the Primary Adverse Factor 1. **Vitiligo as associated condition:** While vitiligo is associated with melanoma risk (both are autoimmune), the presence of vitiligo does not independently worsen melanoma prognosis once the tumor is present. It is a risk factor for development, not a prognostic modifier. 2. **Brisk lymphocytic infiltrate:** A brisk lymphocytic infiltrate (TIL — tumor-infiltrating lymphocytes) is actually a **favorable prognostic sign**, indicating an active immune response against the tumor. It is associated with better outcomes, not worse. 3. **Epithelioid cytomorphology with moderate nuclear pleomorphism:** Epithelioid melanomas do have a slightly worse prognosis than spindle-cell melanomas, but this is a **minor** prognostic factor compared to location (acral vs non-acral), Breslow thickness, and mitotic rate. Moderate (not high) nuclear pleomorphism is not the primary driver of prognosis. ### Prognostic Hierarchy in Melanoma ```mermaid flowchart TD A[Cutaneous Melanoma]:::outcome --> B{Breslow Thickness}:::decision B -->|<1 mm| C[Stage IB-IA]:::outcome B -->|1-2 mm| D[Stage IB-IIA]:::outcome B -->|2-4 mm| E[Stage IIB-IIC]:::outcome B -->|>4 mm| F[Stage III+]:::urgent A --> G{Location}:::decision G -->|Acral/Mucosal| H[Worse Prognosis<br/>ALM]:::urgent G -->|Non-acral| I[Better Prognosis]:::action A --> J{Mitotic Rate}:::decision J -->|<1/mm²| K[Favorable]:::action J -->|≥1/mm²| L[Unfavorable]:::urgent A --> M{TIL Density}:::decision M -->|Brisk/Intermediate| N[Favorable]:::action M -->|Absent| O[Unfavorable]:::urgent ``` **Key Point:** In this case, the acral location (foot) is the **single most important adverse prognostic factor** that overrides other considerations and mandates aggressive staging and follow-up. [cite:Robbins 10e Ch 25]